BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Yes Securities Report
Sequent Scientific Ltd. clocked a steady growth quarter with 11-12% growth across active pharma ingredient and formulations businesses while margin did improve on sequential basis as higher margin API share increased ~200 basis points QoQ.
Management expects to implement price increase at least in some part of long term contracts whose benefit would be gradually seen over course of FY23.
API business rebounded on weak Q3 base as expected though still fell short of expectations.
New Chief Executive Officer reiterated no change in Sequent evolution as focus remains on key markets of India, Latin America, Turkey coupled with U.S. ambition over next three years.
Gross margin improved 100 bps in Q4 and company guided to better operating margin with aspiration to reach FY21 margin – though unlikely in current or next fiscal.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR